Real-world evidence on the benefits of optimal itch relief and skin clearance in atopic dermatitis management: a study from the TARGET-DERM AD registry

Real-world evidence on the benefits of optimal itch relief and skin clearance in atopic dermatitis management: a study from the TARGET-DERM AD registry

Background: In atopic dermatitis (AD), the real-world impact of achieving itch and skin lesion treatment targets compared to partial improvement remains unclear.Objective: We assessed the relationship between itch relief (reduction in Worst Itch Numeric Rating Scale [WI-NRS]) and skin clearance (Inv...

Full description

Saved in:
Bibliographic Details
Main Authors: Jonathan I. Silverberg, Brian M. Calimlim, Ayman Grada, Christopher G. Bunick, Melinda J. Gooderham, Vivian Y. Shi, Chibuzo Obi, Keith D. Knapp, Breda Munoz, Julie M. Crawford, Amy S. Paller
Format: Article
Language:English
Published: Taylor & Francis Group 2024-12-01
Series:Journal of Dermatological Treatment
Subjects:
Atopic dermatitis
pain
itch
skin clearance
quality-of-life
eczema
Online Access:https://www.tandfonline.com/doi/10.1080/09546634.2024.2428729
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Background: In atopic dermatitis (AD), the real-world impact of achieving itch and skin lesion treatment targets compared to partial improvement remains unclear.Objective: We assessed the relationship between itch relief (reduction in Worst Itch Numeric Rating Scale [WI-NRS]) and skin clearance (Investigator Global Assessment [IGA] 0/1) with other patient-reported outcomes.Methods: Using TARGET-DERM AD registry data on adults receiving standard-of-care treatment, we described and modeled the relationship of itch severity (Worst Itch Numeric Rating Scale [WI-NRS]) and skin lesion severity (IGA) outcomes with patient-reported (quality of life ([DLQI)], AD severity [(POEM]), sleep ([Sleep-NRS]), and skin pain [(Pain-NRS]).Results: Among 1,920 participants (58.6% female; 54.5% Non-Hispanic White; 93.8% US; mean age 45 years), ideal outcomes (DLQI 0/1, POEM 0-2, Sleep-NRS 0/1, and Pain-NRS 0/1) were most frequent for those achieving the optimal targets for itch (WI-NRS 0/1; 52.1%, 53.7%, 57.3%, and 83.1%, respectively) and skin clearance (IGA 0/1; 44.7%, 44.3%, 44.7%, and 74.3%, respectively). The odds ratios of ideal outcomes were greatest for participants with complete or near-complete resolution of both itch and skin (DLQI 0/120.0; POEM 0-2: 41.7; Sleep-NRS: 16.1; Pain-NRS: 6.0).Conclusions: Achieving optimal treatment targets for both itch and skin lesion improvement markedly enhances patient-reported AD outcomes. The results of this study support using minimal disease activity criteria to assess therapeutic effectiveness.
ISSN:0954-6634
1471-1753

Similar Items